- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about PCVX
Recent news which mentions PCVX
From Benzinga
From Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 31, 2025
From Benzinga
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet
March 31, 2025
From Benzinga
Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March
March 31, 2025
From Benzinga
From Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 31, 2025
From Benzinga
One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
March 15, 2025
From Motley Fool
Are Small-Cap Stocks A Buy After Russell 2000 Correction?
March 06, 2025
From Benzinga
Earnings Scheduled For February 25, 2025
February 25, 2025
From Benzinga
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank
December 17, 2024
From Motley Fool
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
November 20, 2024
From Motley Fool
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
November 17, 2024
From Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 03, 2024
From Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
September 03, 2024
From Benzinga
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
September 03, 2024
From Benzinga
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
April 10, 2024
From Benzinga
From Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
From Benzinga
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
January 05, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.